Search Results
Sep 09, 2026, 05:00 ET Terapia de edición bases con tBE logra remisión clínica duradera en drepanocitosis y β-talasemia en varios fondos genét
de bases sin cortar el ADN, evitando la activación de p53, la apoptosis, las grandes deleciones y las reordenaciones cromosómicas. Su diseño dual de gRNA y "llave-cerradura" minimiza aún más los riesgos de efectos fuera de objetivo. Mediante un "cerradura" escindible, tBE se activa únicamente en los sitios
More news about: CorrectSequence Therapeutics
Sep 08, 2026, 12:52 ET Cell Stem Cell: Die tBE-vermittelte Base-Editing-Therapie erzielt bei unterschiedlichen genetischen Hintergründen eine dauerhafte klinische Remission bei Sichelzellkrankheit und β-Thalassämie
Basenumwandlung, ohne die DNA zu spalten, wodurch die Aktivierung von p53, Apoptose, große Deletionen und chromosomale Umlagerungen vermieden werden. Sein duales gRNA- und „Schlüssel-Schloss"-Design minimiert das Risiko von Off-Target-Effekten zusätzlich. Durch ein spaltbares „Schloss" wird tBE nur an den Zielstellen
More news about: CorrectSequence Therapeutics
Sep 08, 2026, 10:41 ET Cell Stem Cell : la thérapie d'édition de bases médiée par tBE permet d'obtenir une rémission clinique durable dans la drépanocytose et la bêta-thalassémie, quel que soit le profil génétique des patients
l'ADN, ce qui évite l'activation de p53, l'apoptose, les délétions importantes et les réarrangements chromosomiques. Sa conception à double ARN guide (gRNA) et de type « verrou-clé » réduit encore davantage les risques de ciblage hors cible. Grâce à un « verrou » clivable, tBE ne s'active qu'au niveau des
More news about: CorrectSequence Therapeutics
Sep 07, 2026, 20:00 ET Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
tBE enables precise base conversion without cutting DNA, avoiding p53 activation, apoptosis, large deletions, and chromosomal rearrangements. Its dual gRNA and "lock-and-key" design further minimizes off-target risks. Through a cleavable "lock", tBE becomes active only at on-target sites to induce highly
More news about: CorrectSequence Therapeutics
Sep 07, 2026, 20:00 ET Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
tBE enables precise base conversion without cutting DNA, avoiding p53 activation, apoptosis, large deletions, and chromosomal rearrangements. Its dual gRNA and "lock-and-key" design further minimizes off-target risks. Through a cleavable "lock", tBE becomes active only at on-target sites to induce highly
More news about: CorrectSequence Therapeutics
Sep 02, 2026, 09:00 ET New Johns Hopkins Study Identifies Pervasive RT-qPCR Artifact in CRISPR Knockdown Studies and How UltraMarathonRT® Solves It
cDNA synthesis was directly blocked by the tightly bound guide RNA (gRNA) itself. With bound gRNA preventing the enzyme from reading through the guide-binding region, any RT-qPCR amplicon spanning or sitting just upstream of the gRNA site was suppressed as a result, artificially indicating knockdown
More news about: RNAConnect
Jul 09, 2026, 13:06 ET GEMMABio Awarded ARPA-H Funding to Pursue Innovative Base-editing Strategy for Rare Liver Diseases
and powerful base-editing approach that can be applied across diverse mutations and genetic diseases where the only unique component is guide RNA (gRNA). We believe these attributes may permit significant cost reductions and have the potential to increase access around the world.""Profluent has
More news about: GEMMA Biotherapeutics
Jul 07, 2026, 10:01 ET Gene Editing Market to Reach US$30.5 Billion by 2033 as Precision Medicine and CRISPR Innovation Accelerate Growth - Persistence Market Research
CRISPR Gene-Editing Market by Product (Kits & Enzymes, Libraries, Others), Service (gRNA Design and Vector Construction, Cell Line Engineering, Screening Services, Other), Application, and Regional Analysis, 2026 - 2033
More news about: Persistence Market Research Pvt. Ltd.
May 25, 2026, 08:45 ET A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
gene in the liver and durably reduces disease-driving LDL-C. VERVE-102 consists of a messenger RNA encoding an adenine base editor and a guide RNA (gRNA) targeting the PCSK9 gene. Both are encapsulated in a lipid nanoparticle (LNP) and administered as a single intravenous infusion over approximately
More news about: Eli Lilly and Company
Apr 01, 2026, 15:59 ET Synthego Welcomes Supreme Court Order Finalizing Invalidation of Agilent CRISPR Patents
life-changing therapies."With the chain of appeals now exhausted, the invalidation of these patents removes a significant barrier to the use of essential gRNA modifications, fostering an environment where innovation in CRISPR-enabled research and therapeutics can flourish.About SynthegoSynthego
More news about: Synthego
Mar 19, 2026, 10:01 ET Preimplantation Genetic Testing Market to Reach US$ 1,081.9 Million by 2033 Amid Rising IVF Adoption and Technological Innovation - Persistence Market Research
CRISPR Gene-Editing Market by Product (Kits & Enzymes, Libraries, Others), Service (gRNA Design and Vector Construction, Cell Line Engineering, Screening Services, Other), Application, and Regional Analysis, 2026 – 2033
More news about: Persistence Market Research Pvt. Ltd.
Oct 31, 2025, 06:52 ET ICHORtec और Johns Hopkins University ने Quantum FMB® तकनीक का उपयोग करके CRISPR जीन संपादन विशिष्टता को बढ़ाने के लिए सहयोग का विस्तार किया
सहयोग की घोषणा कर ते हुए खुशी हो रही है। यह साझेदारी, अंतर्राष्ट्रीय Quantum विज्ञान और तकनीकी वर्ष (IYQ) 2025 के साथ संरेखित है, जो CRISPR गाइड RNA (gRNA) डिजाइन और मूल्यांकन की सटीकता को आगे बढ़ाने के लिए ICHORtec की स्वामित्व वाली क्वांटम फ्लोरीमेट्री ऑफ़ मॉलिक्यूलर बाइंडिंग (Q-FMB®) तकनीक
More news about: ICHORtec GmbH
Oct 29, 2025, 09:00 ET ICHORtec and Johns Hopkins University Expand Collaboration to Enhance CRISPR Gene Editing Specificity Using Quantum FMB® Technology
leverages ICHORtec's proprietary Quantum Fluorimetry of Molecular Binding (Q-FMB®) technology to advance the precision of CRISPR guide RNA (gRNA) design and evaluation, minimizing off-target effects in gene editing therapies. The collaboration centers on ICHORtec's Quantum
More news about: ICHORtec GmbH
Oct 29, 2025, 09:00 ET ICHORtec and Johns Hopkins University Expand Collaboration to Enhance CRISPR Gene Editing Specificity Using Quantum FMB® Technology
leverages ICHORtec's proprietary Quantum Fluorimetry of Molecular Binding (Q-FMB®) technology to advance the precision of CRISPR guide RNA (gRNA) design and evaluation, minimizing off-target effects in gene editing therapies.
More news about: ICHORtec GmbH